7Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung can- cer to gefitinib. N EnglJ Med, 2004, 350(21): 2129-2139.
8XuJM, Han Y, Duan HOt et al. EGFR mutations and HER2/3 protein ex pression and clinical outcome in chinese advanced non-small cell lung can cer patients treated with gefitinib. J Cancer Res Clin Oncol, 2009, 135(6) 771-782.
9Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer, 2006, 42(1): 17-23.
10Zhu JOa Zhong WZ, Zhang GC, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Lett, 2008, 265(2): 307-317.
4Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patient s wit h advanced non small cell lung cancer. J Natl Cancer Inst,2005,97(6) :461 - 462.
5West KA, Brognard J, Clark AS, et al. Rapid Akt activation by nicotine and a tobacco caricogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest ,2003,111:81 - 90.
6Balsam B R, Pei J, Mit suuchi Y, et al. Frequent activation of AKT in non small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis ,2004,25 ( 11 ) :2053 - 2059.
7Drevs J, Medinger M, Schmidt Gersbach C, et al. Receptor tyrosine kinases:the main targets for new anticancer therapy. Cure Drug Targets, 2003,4:113 - 121.
8Adjei AA. Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res,2006,12(14) :4446 -4450.
9Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer ceils and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 2001,61 (10) :3986 - 3997.
10Tang JM, He Q Y, Guo RX, et al. Phosphorylated Akt overex pression and loss of PTEN expression in non small cell lung cancer confers poor prognosis. Lung Cancer,2006,51 (2) :181 - 191.
8Custodio A,Mendez M,Provencio M.Targeted therapies for advanced non-small-cell lung cancer:current status and future implications.Cancer Treat Rev,2012,38(1):36-53.
9Mendelsohn J.Blockade of receptors for growth factors:an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.Clin Cancer Res,2000,6(3):747-753.
10Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin Cancer Res,2001,7(5):1459-1465.
